| 证券代码 | CBMX.O |
| 证券名称 | CombiMatrix Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2002-12-16 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | CombiMatrix Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 310 Goddard, Suite 150, Irvine, California, USA |
| 成立日期 | 1995-10 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.combimatrix.com |
| 电话 | +1 (949) 753-0624 |
| 传真 | +1 (949) 753-1504 |
| 公司简介 | CombiMatrix Corporation is a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It strives to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Its testing focuses on advanced technologies, including single nucleotide polymorphism, or SNP, chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization, or FISH, and high resolution chromosome analysis (also referred to as karyotyping). Its approach to testing is to offer sophisticated technology along with high quality clinical support to its ordering physicians and their patients. Its laboratory facilities and corporate headquarters are located in Irvine, California. It also owns a one-third minority interest in Leuchemix, Inc., a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases. |